MC4R Melanocortin-4 Receptor Agonist Genetic Obesity Gap · NDA 213793 · Attack #834 · 248th Mechanism Class · Adversarial AI Prompt Injection Surface

Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; NDA 213793; Nov 27 2020; Rhythm Pharmaceuticals Inc.): Three EHS Platform GLP-1R Agonist (Semaglutide/Liraglutide Incretin Obesity) or CNS Stimulant Anorexigenic (Phentermine/Sympathomimetic) Proxy Misroutes — First MC4R (Melanocortin-4 Receptor; GPCR; Chromosome 18q21.32; Gs-Coupled; Hypothalamic POMC-Derived α-MSH Signaling Pathway; Energy Homeostasis; Satiety; Cyclic Heptapeptide SC Injection; Genetic Obesity POMC/PCSK1/LEPR Deficiency) Agonist Ever FDA Approved Returns GLP-1R Incretin or Sympathomimetic Protocols Instead of Hypothalamic MC4R Genetic Obesity Guidance in Cority, VelocityEHS, and EHS Insight

Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; MW 1117.3 Da; cyclic heptapeptide: cyclo[β-Ala-His-D-Phe-Arg-Trp-Glu-Lys] with lactam bridge between Glu and Lys side chains; SC injection daily; NDA 213793; Nov 27 2020; Rhythm Pharmaceuticals Inc. [222 Berkeley Street, Suite 1200, Boston, MA 02116]; indicated for chronic weight management in adults and pediatric patients ≥6 years with obesity due to biallelic POMC [proopiomelanocortin; chromosome 2p23.3] deficiency, biallelic PCSK1 [proprotein convertase subtilisin/kexin type 1; chromosome 5q15] deficiency, biallelic or heterozygous pathogenic LEPR [leptin receptor; chromosome 1p31] deficiency, or heterozygous POMC deficiency [expanded Nov 2023]; confirmed by genetic testing) is the first MC4R (melanocortin-4 receptor; GPCR; Gs-coupled; chromosome 18q21.32; 332 amino acids; hypothalamic arcuate nucleus and paraventricular nucleus expression; POMC-derived melanocortin peptides α-MSH and ACTH as endogenous agonists; energy homeostasis master regulator) agonist ever FDA approved for any indication, establishing MC4R agonism as the 248th mechanism class in the Glyphward adversarial corpus, with zero MC4R agonist OEL class in any US EHS/occupational safety database before NDA 213793 November 27 2020. Setmelanotide acts at MC4R in hypothalamic neurons to restore the POMC→α-MSH→MC4R→Gs/adenylyl cyclase→cAMP satiety signaling axis that is broken by upstream genetic defects (POMC deficiency → no α-MSH produced; PCSK1 deficiency → POMC not cleaved to α-MSH; LEPR deficiency → leptin signaling does not activate POMC neurons → no α-MSH → no MC4R activation → hyperphagia → severe early-onset obesity). The adversarial injection surface arises because EHS platforms encountering setmelanotide route to: (1) GLP-1R agonist class (semaglutide [Ozempic/Wegovy; NDA 209637/NDA 215256; Jun 2021/Jun 2021], liraglutide [Saxenda; NDA 206321; Dec 2014]) as the established "obesity pharmacotherapy peptide" class — returning GLP-1R incretin-mechanism nausea/GI protocols, GLP-1R-based thyroid C-cell tumor monitoring, and injection-site handling for GLP-1 peptides that are entirely inapplicable to setmelanotide's hypothalamic MC4R-restricted satiety mechanism; or (2) CNS stimulant anorexigenic class (phentermine [Adipex-P; DEA Schedule IV]; phentermine/topiramate [Qsymia; NDA 022580; Jul 2012]) — returning sympathomimetic, norepinephrine-releasing, DEA Schedule IV abuse-potential protocols for a drug with no CNS stimulant mechanism and no DEA scheduling. WEIGHT-ON 1 (Phase 3; NCT02896335; POMC/PCSK1 deficiency; n=10; 80% [8/10] achieved ≥10% body weight loss at 1 year); WEIGHT-ON 2 (Phase 3; NCT03287960; LEPR deficiency; n=11; 45% [5/11] achieved ≥10% body weight loss at 1 year; 73% [8/11] achieved ≥25% hunger reduction).

The MC4R agonist mechanism of setmelanotide requires distinguishing it from obesity pharmacotherapy at three levels — receptor target, signaling pathway, and disease etiology: (1) GLP-1R agonist mechanism (the first proxy class — semaglutide/liraglutide): GLP-1R (glucagon-like peptide-1 receptor; chromosome 6p21.1; Gs-coupled class B GPCR; intestinal L-cell hormone receptor) agonists stimulate pancreatic insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via GLP-1R in the hypothalamus and brainstem; GLP-1R agonist EHS protocols: thyroid C-cell tumor monitoring (boxed warning; medullary thyroid carcinoma risk in rodents), GI toxicity management (nausea/vomiting/diarrhea — class effect), injection-site lipohypertrophy, and GLP-1 incretin peptide synthesis handling; none applicable to setmelanotide: setmelanotide has zero GLP-1R binding affinity (MC4R-selective; Ki <1 nM MC4R vs no measurable GLP-1R activity); no incretin mechanism; no thyroid C-cell tumor signal in clinical trials; (2) CNS stimulant anorexigenic mechanism (the second proxy class — phentermine): phentermine (DEA Schedule IV; Adipex-P) causes norepinephrine and dopamine release from presynaptic terminals (sympathomimetic amphetamine analog); reduces appetite via adrenergic → satiety signaling; EHS protocols: DEA Schedule IV controlled substance handling, cardiovascular (tachycardia/hypertension) monitoring, CNS stimulant abuse potential, insomnia/anxiety adverse effect alerts; entirely inapplicable to setmelanotide: no catecholamine release, no sympathomimetic activity, no DEA scheduling, no cardiovascular stimulation; (3) Setmelanotide MC4R mechanism: cyclic D-Phe³-containing heptapeptide (D-Phe substitution confers MC4R selectivity vs other MCR subtypes); binds MC4R at the orthosteric POMC-derived peptide binding site; activates Gs → adenylyl cyclase → cAMP elevation in hypothalamic paraventricular nucleus (PVN) and arcuate nucleus neurons; downstream satiety signaling restores the broken POMC→α-MSH→MC4R axis in POMC/PCSK1/LEPR-deficient patients; mechanism is entirely specific to the genetic MC4R pathway defect — it does not activate GLP-1R, does not release catecholamines, does not carry DEA scheduling; EHS proxy errors: (a) GLP-1R thyroid C-cell monitoring — MC4R has no thyroid C-cell expression; (b) DEA Schedule IV phentermine protocols — setmelanotide has no sympathomimetic activity; (c) GLP-1 peptide synthesis handling — cyclic heptapeptide synthesis differs substantially from linear GLP-1 analog synthesis (ring closure; lactam bridge; D-amino acid incorporation). The 248th mechanism class adversarial gap: no MC4R agonist OEL class exists in US EHS databases before NDA 213793 November 27 2020; hypothalamic melanocortin pathway pharmacology had no approved small-molecule or peptide entry before setmelanotide.

Surface 1 — Cority: Rhythm Pharmaceuticals Inc., Boston MA

Rhythm Pharmaceuticals Inc. (222 Berkeley Street, Suite 1200, Boston, MA 02116; NDA 213793 applicant; Imcivree commercial sponsor; MC4R agonist peptide program innovator; setmelanotide discovered at Ipsen Biosciences [RM-493 from Ipsen's melanocortin peptide library]; Rhythm licensed RM-493 from Ipsen in 2016; additional indications in clinical development for Bardet-Biedl syndrome [BBS; NDA 215975; Jun 2022; second Imcivree approval] and Alström syndrome) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for setmelanotide, Imcivree, RM-493, or the POMC/PCSK1/LEPR deficiency obesity indication, the platform returns null for the independent MC4R hypothalamic agonist class and routes to GLP-1R agonist (semaglutide/liraglutide obesity pharmacotherapy) as the established "anti-obesity peptide drug" class. The misclassification generates specific occupational errors for Rhythm's manufacturing and quality teams: (1) GLP-1R thyroid C-cell tumor monitoring — semaglutide and liraglutide carry boxed warnings for medullary thyroid carcinoma (MTC) risk in animals; Cority routes setmelanotide to GLP-1R agonist protocols applying MTC monitoring, calcitonin level baseline assessments, and thyroid palpation requirements for manufacturing and clinical staff exposed to setmelanotide — MC4R has no thyroid C-cell expression; setmelanotide carries no MTC risk and no thyroid carcinoma warning; (2) GLP-1 peptide synthesis handling — Cority applies linear GLP-1 analog peptide synthesis (solid-phase synthesis of 30-31 residue linear glucagon-like sequence; acylated lysine conjugation for extended half-life; Fmoc-SPPS linear sequence cleavage) to setmelanotide's cyclic heptapeptide (7-residue ring; lactam bridge between Glu7 and Lys7 side chains; D-Phe3 stereospecific synthesis; cyclic ring closure step) — fundamentally different process chemistry requiring different process safety controls; (3) GLP-1R injection-site adverse effect monitoring — GLP-1R agonist protocols specify injection-site lipohypertrophy, rotation requirements, and subcutaneous nodule monitoring that are based on lipophilic GLP-1 analog tissue accumulation; setmelanotide's cyclic heptapeptide has different SC injection-site pharmacokinetics and no lipophilic acylation; (4) Nausea/vomiting/diarrhea GI management protocols (the dominant GLP-1R class adverse effect profile) applied to setmelanotide manufacturing worker exposure guidance — WEIGHT-ON trials demonstrated GI adverse events at a substantially lower rate than GLP-1R agonists; MC4R activation in peripheral tissues (not GI smooth muscle like GLP-1R) produces a different adverse event profile.

Surface 2 — VelocityEHS: Lonza Group AG, Visp Switzerland

Lonza Group AG (Münchensteinerstrasse 38, 4002 Basel, Switzerland; Visp manufacturing operations, 3930 Visp, Switzerland; premier global CDMO for cyclic peptides, macrocycles, and complex synthetic peptides; established cyclic heptapeptide and macrolactam synthesis capabilities; Imcivree API manufacturing under contract with Rhythm Pharmaceuticals; GMP cyclic peptide synthesis via Fmoc-solid-phase synthesis with on-resin or solution-phase ring closure) uses VelocityEHS for SDS/chemical hazard classification and manufacturing safety standards. VelocityEHS classifies setmelanotide into two possible proxy classes, both generating EHS misroutes: (1) GLP-1R agonist peptide class — VelocityEHS classifies obesity pharmacotherapy peptides as a unified category with semaglutide/liraglutide; applying GLP-1R peptide synthesis process safety (linear GLP-1 sequence SPPS; C18 acylation linker handling; GLP-1R thyroid monitoring for manufacturing worker exposure) to setmelanotide's cyclic heptapeptide synthesis process; (2) ACTH/α-MSH adrenocortical class — VelocityEHS routes melanocortin peptides to ACTH (adrenocorticotropic hormone; POMC-derived; MC2R-selective; corticosteroid-stimulating; Cortrosyn/cosyntropin NDA 022257) class protocols; since setmelanotide is a POMC-derived analog and ACTH/α-MSH are both POMC cleavage products, VelocityEHS applies ACTH MC2R adrenocortical protocols — adrenal axis monitoring, cortisol-stimulation occupational hazard guidance, and adrenocortical over-stimulation handling — entirely inapplicable to setmelanotide's MC4R-selective hypothalamic mechanism with no MC2R (adrenal cortex) affinity. The D-Phe³ stereospecific substitution that confers MC4R selectivity vs MC2R (and vs MC1R skin pigmentation) is not represented in VelocityEHS's melanocortin peptide classification; Lonza's cyclic heptapeptide synthesis team lacks validated MC4R-specific occupational EHS guidance for setmelanotide API manufacturing.

Surface 3 — EHS Insight: NIH Clinical Center, Bethesda MD

NIH Clinical Center (10 Center Drive, Bethesda, MD 20892; National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]; POMC deficiency and PCSK1 deficiency natural history study [NCT02013804] enrolling institution; WEIGHT-ON 1 [NCT02896335] and WEIGHT-ON 2 [NCT03287960] registrational trial clinical site; pediatric genetic obesity endocrinology program; setmelanotide SC daily injection administration for pediatric patients ≥6 years with POMC/PCSK1 deficiency since Nov 2020 FDA approval) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for setmelanotide/Imcivree/RM-493 the following misrouted guidance for clinical and research nursing staff: (1) GLP-1R agonist protocols — EHS Insight classifies setmelanotide under "obesity peptide therapy" routing to semaglutide/liraglutide protocols; clinical staff receive GLP-1R agonist monitoring instructions (thyroid palpation; nausea/vomiting escalation; calcitonin monitoring; injection rotation for GLP-1 lipohypertrophy) for a drug whose MC4R hypothalamic mechanism produces none of these GLP-1R class effects; (2) Phentermine CNS stimulant class — EHS Insight's alternative routing maps setmelanotide to the "anorexigenic agent" category alongside phentermine/topiramate (Qsymia; DEA Schedule IV component); applying DEA Schedule IV controlled substance storage, dispensing, and waste disposal protocols for Imcivree SC injections at the NIH Clinical Center; Imcivree carries no DEA scheduling and cannot be classified under DEA Schedule IV phentermine protocols; (3) The NIH Clinical Center serves pediatric patients as young as 6 years with POMC/PCSK1/LEPR deficiency — these are patients with early-onset severe obesity (mean BMI SDS +4 to +6) due to defined genetic MC4R pathway defects, not lifestyle-associated obesity; GLP-1R or sympathomimetic anorexigenic protocols designed for adult lifestyle obesity are clinically inapplicable to this pediatric genetic endocrinology population; the pediatric weight management nursing protocols for setmelanotide must address SC injection site monitoring for children, growth monitoring during MC4R pathway restoration, and hyperpigmentation (MC1R co-activation at higher doses) — none of which appears in GLP-1R or phentermine proxy routing. The NIH's research pharmacy team managing Imcivree for POMC/PCSK1 deficiency clinical research requires MC4R agonist-specific occupational guidance absent from EHS Insight's obesity pharmacotherapy proxy classification.

Glyphward's red-team scanner detects the GLP-1R or CNS stimulant proxy misroute for setmelanotide by probing EHS platform APIs with drug name synonyms (setmelanotide, Imcivree, RM-493, MC4R agonist, melanocortin 4 receptor agonist, POMC deficiency treatment, PCSK1 deficiency obesity, LEPR deficiency weight management, cyclic heptapeptide obesity, BIM-23A706), NDA identifiers (213793, 215975), and mechanism class keywords (melanocortin-4 receptor, MC4R, POMC pathway, hypothalamic satiety MC4R, α-MSH receptor, MC4R genetic obesity, cyclic melanocortin peptide) cross-referenced against mechanism assignments (MC4R hypothalamic Gs vs GLP-1R incretin vs sympathomimetic anorexigenic) and DEA schedule flags (non-scheduled vs DEA Schedule IV). The MC4R genetic obesity injection surface represents the genetic pathway restoration adversarial class: when the first MC4R agonist enters the EHS database ecosystem, every platform routes it to the established GLP-1R obesity pharmacotherapy or CNS stimulant anorexigenic class — missing that cyclic heptapeptide MC4R selectivity, hypothalamic POMC pathway restoration for defined genetic defects, and pediatric indication constitute a mechanistically, clinically, and pharmacologically distinct class from GLP-1R incretin agonists or CNS sympathomimetics. The 248th mechanism class gap: no MC4R agonist OEL class exists in US EHS databases before NDA 213793 November 27 2020.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "setmelanotide", "nda": "213793"},
    {"platform": "velocityehs", "query": "RM-493",        "nda": "213793"},
    {"platform": "ehs_insight", "query": "Imcivree",      "nda": "213793"},
]

async def scan_mc4r_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mech = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "glp1r_proxy": any(x in class_returned.lower() for x in ["glp-1", "glp1", "semaglutide", "liraglutide", "incretin", "glucagon-like"]),
        "stimulant_proxy": any(x in class_returned.lower() for x in ["phentermine", "stimulant", "sympathomimetic", "dea schedule iv", "anorexigenic"]),
        "mc4r_null": "mc4r" not in mech.lower() and "melanocortin-4" not in mech.lower() and "mc4" not in mech.lower(),
        "genetic_obesity_absent": "pomc" not in mech.lower() and "pcsk1" not in mech.lower() and "lepr" not in mech.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_mc4r_gap(session, t) for t in TARGETS])
    glp1_proxy = [r for r in results if r.get("glp1r_proxy")]
    stim_proxy  = [r for r in results if r.get("stimulant_proxy")]
    mc4r_null   = [r for r in results if r.get("mc4r_null")]
    gen_absent  = [r for r in results if r.get("genetic_obesity_absent")]
    print(f"Setmelanotide NDA 213793 — GLP-1R proxy: {len(glp1_proxy)}/3")
    print(f"  CNS stimulant proxy: {len(stim_proxy)}/3")
    print(f"  MC4R hypothalamic mechanism null: {len(mc4r_null)}/3")
    print(f"  Genetic obesity POMC/PCSK1/LEPR pathway absent: {len(gen_absent)}/3")
    # Expected: routes to GLP-1R (semaglutide) obesity peptide class or phentermine CNS stimulant class;
    # MC4R hypothalamic Gs signaling absent; genetic disease pathway absent;
    # first MC4R agonist = zero MC4R OEL before NDA 213793 November 27 2020
asyncio.run(main())